Influence of probiotic in oral and intestinal microbiota of individuals with periodontitis and with Diabetes mellitus type 2 using in vitro colonic model

• Grant number: 19/17794-6
• Support type: Regular Research Grants
• Duration: July 01, 2020 - December 31, 2022
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal researcher: Katia Sivieri
• Grantee: Katia Sivieri
• Home Institution: Anhanguera Educacional S/A (AESA). São Bernardo do Campo , SP, Brazil
• Assoc. researchers: Marcia Pinto Alves Mayer ; Silvana Regina Perez Orrico ; Susana Nogueira Diniz ; Tânia Aguiar Passeti ; Waleska Kerllen Martins Gardesani
• Associated grant(s): 20/00218-0 - Potential probiotic strains isolated from human breast milk: are they able to modulate the intestinal microbiota of obese children?, AP.R SPRINT

Abstract

Type 2 diabetes mellitus (DMT2) is a highly prevalent metabolic disorder, with genetic constituents, high-fat, high-energy eating habits and a sedentary lifestyle being three main factors that contribute to the high risk of type 2 diabetes. studies have reported dysbiosis of the intestinal microbiome as a factor in the rapid progression of insulin resistance in DMT2, responsible for about 90% of all diabetes cases worldwide. On the other hand, people with diabetes are 2.5 times more likely than non-diabetic patients to develop periodontal disease. The dysbiosis of the intestinal microbiome can remodel the functions of the intestinal barrier and host the metabolic and signaling pathways, which are directly or indirectly related to insulin resistance in DMT2. Any change in the intestinal microbiota can alter the host's metabolism to increase energy production during diabetes and obesity. Thus, the objective of this work is to evaluate the effect of the probiotic Lactobacillus acidophilus La-5 on the oral and colon microbiome, metabolism of the colon microbial population and immunological parameters using the Human Microbial Ecosystem Simulator (SEMH®). The experimental protocol will be performed in triplicate, with a sample of collection of supra and subgingival plaque and feces from four groups: Group 1: individuals with periodontal disease; Group 2: individuals with type 2 diabetes mellitus and Group 3: individuals with type 2 diabetes mellitus and periodontal disease; Group 4: individuals without type 2 diabetes mellitus and periodontal disease (Control Group). SEMH® reactor samples will be evaluated for oral and intestinal microbiome (sequencing of the 16S rRNA gene and for microbial metabolism (NH4 + and short chain fatty acids) .In addition, the immunomodulatory effects of the different metabolites derived from colonic reactors will be evaluated using Caco-2 cell and THP1-Xbluea cells co-culture model. (AU)